![Thomas F. Baumert](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Oorsprong van het eerstegraads netwerk van Thomas F. Baumert
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Alentis Therapeutics AG
![]() Alentis Therapeutics AG Pharmaceuticals: MajorHealth Technology Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland.
11
| Holding Company | Pharmaceuticals: Major | 11 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Thomas F. Baumert via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
FLEXION THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO | |
VectivBio AG
![]() VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member Founder | |
Pureos Partners AG
![]() Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Investment Managers | Private Equity Investor Private Equity Investor | |
ENYO Pharma SA
![]() ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France. | Biotechnology | Director/Board Member Director/Board Member | |
Apic Bio, Inc.
![]() Apic Bio, Inc. Packaged SoftwareTechnology Services Apic Bio, Inc. engages in the development of treatment for neurological and liver diseases. It offers THRIVE, a platform that silences a mutant gene product and replaces a normal gene product in a single dual function vector. The company was founded by Robert H. Brown, Jr., John Reilly, and Christian Mueller in 2017 and is headquartered in North Cambridge, MA. | Packaged Software | Director/Board Member | |
The University of Iowa College of Law | College/University | Graduate Degree | |
Iowa State University | College/University | Doctorate Degree | |
KEZAR LIFE SCIENCES, INC. | Biotechnology | Director/Board Member | |
Alms Therapeutics SAS
![]() Alms Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Alms Therapeutics SAS provides research and development in the treatment of diabetes. The company was founded by Jason Robert Dinges on July 4, 2017 and is headquartered in Paris, France. | Miscellaneous Commercial Services | Founder | |
Pinteon Therapeutics, Inc.
![]() Pinteon Therapeutics, Inc. BiotechnologyHealth Technology Pinteon Therapeutics, Inc. develops cancer and CNS therapeutics. It focuses on the discovery and development of therapeutics targeting Pin1. The firm specializes in aberrant disease processes and improves patient outcomes in medical need indications. The company is headquartered in Newton Centre, MA. | Biotechnology | Director/Board Member | |
CellCentric Ltd.
![]() CellCentric Ltd. Pharmaceuticals: MajorHealth Technology CellCentric Ltd. develops and commercializes small molecule inhibitors for cancer. Its active programs include inhibitors to histone methyltransferases, histone demethylases and epigenetic enzymes that act via ubiquitin. The company was founded by Alun Huw Jones, Catherine Denise Prescott, Azim Surani and William Henry Lewarne West in May 2004 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
2020, Inc.
![]() 2020, Inc. Medical/Nursing ServicesHealth Services 2020, Inc. offers eye care services. It also offers delivers on-site eye care and eye exams to businesses and their employees via a mobile eye clinic. The company was founded by Howard Bornstein in 2013 and is headquartered in Boston, MA. | Medical/Nursing Services | Director/Board Member | |
Cancer Targeting Systems, Inc.
![]() Cancer Targeting Systems, Inc. BiotechnologyHealth Technology Cancer Targeting Systems, Inc. offers cancer care. The firm focuses on delivering cancer theranostic products combining imaging with therapy. The company was founded by Martin Pomper and Will West and is headquartered in Boston, MA. | Biotechnology | Director/Board Member | |
Cimeio Therapeutics AG
![]() Cimeio Therapeutics AG Packaged SoftwareTechnology Services Cimeio Therapeutics AG is an applied gene editing and immunotherapy company based in Basel, Switzerland. Cimeio is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip) that have the potential to transform hematopoietic stem cell transplant. The Swiss company's technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in hscs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. Cimeio is the leader of the field of epitope editing and is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip), novel immunotherapies which have the potential to transform treatment of hematologic diseases. The company develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in hscs. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. The company was founded by Lukas Jeker and the CEO is Thomas Fuchs. | Packaged Software | Director/Board Member | |
Phase4 Partners Ltd.
![]() Phase4 Partners Ltd. Investment ManagersFinance Phase4 Ventures ltd (Phase4 Ventures) is a venture capital subsidiary of Nomura International Plc founded in 1999. The firm is headquartered in London, UK. | Investment Managers | Investment Committee Member | |
ROCHE HOLDING AG | Pharmaceuticals: Major | Corporate Officer/Principal | |
Inotrem SA
![]() Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
University of Turin | College/University | Doctorate Degree | |
Therachon SAS
![]() Therachon SAS BiotechnologyHealth Technology TherAchon SAS provides biotechnology services. It specializes in research and development for achondroplasia and its associated complications. The company was founded by Elvire Gouze in 2014 and is headquartered in Biot, France. | Biotechnology | Chief Executive Officer | |
Ariceum Therapeutics GmbH
![]() Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | Miscellaneous Commercial Services | Director/Board Member | |
Binx Health Ltd.
![]() Binx Health Ltd. Miscellaneous Commercial ServicesCommercial Services Part of binx health, inc., Binx Health Ltd. is a British company that engages in research and development on biotechnology. The company is based in Trowbridge, UK. The company was founded in 2005. The CEO is Jeffrey R. Luber. | Miscellaneous Commercial Services | Director/Board Member | |
YPSOMED HOLDING AG | Medical Specialties | Director/Board Member | |
BB Biotech Ventures | Chief Executive Officer | ||
Opsona Therapeutics Ltd.
![]() Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member | |
Foley & Lardner LLP
![]() Foley & Lardner LLP Miscellaneous Commercial ServicesCommercial Services Foley & Lardner LLP engages in the provision of legal services. Its practice areas include employee benefits and executive compensation, environmental, estates and trusts, finance, international tax and transfer pricing, private equity and venture capital, real estate, securities, commodities and exchange regulation, taxation, and transactions. The company was founded by Asahel Finch and William Pitt Lynde on September 8, 1842 and is headquartered in Milwaukee, WI. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
GreenLight Biosciences, Inc.
![]() GreenLight Biosciences, Inc. BiotechnologyHealth Technology GreenLight Biosciences, Inc. engages in a biotechnology company.. It delivers attractive solution for production of chemicals and fuels from renewable resources, eliminating the need for petroleum feedstocks. The company was founded by Andrey J. Zarur, Marta Ortega-Valle, and James R. Swartz and is headquartered in Medford, MA. | Biotechnology | Director/Board Member | |
Prilenia Therapeutics BV
![]() Prilenia Therapeutics BV BiotechnologyHealth Technology Prilenia Therapeutics BV develops and manufactures pharmaceuticals. The company was founded in 2018 and is headquartered in Naarden, the Netherlands. | Biotechnology | Director/Board Member | |
International Institute for Management Development | College/University | Masters Business Admin | |
Ridgeline Therapeutics | Founder | ||
Bright Peak Therapeutics AG
![]() Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | Biotechnology | Head-Fixed Income Invts | |
Tridek-One Therapeutics SAS
![]() Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Miscellaneous Commercial Services | Director/Board Member | |
Igyxos SA
![]() Igyxos SA Pharmaceuticals: MajorHealth Technology Igyxos SA engages in the development of an innovative medical and pharmaceutical technologies in the field of human fertility. It is involved in all phases of development, from the discovery of promising targets to the identification of potential lead compounds. The company was founded by Marie-Christine Maurel and is headquartered in Nouzilly, France. | Pharmaceuticals: Major | Director/Board Member | |
Novartis Pharma AG
![]() Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
The University of Chicago | College/University | Masters Business Admin | |
Heidelberg University (Ohio) | College/University | Doctorate Degree | |
ABLYNX | Biotechnology | Corporate Officer/Principal | |
Azafaros BV
![]() Azafaros BV Pharmaceuticals: MajorHealth Technology Azafaros BV develops therapeutic agents for the treatment of rare metabolic disorders. The company was founded on July 1, 2018 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
Ventaleon GmbH
![]() Ventaleon GmbH Pharmaceuticals: OtherHealth Technology Ventaleon GmbH is a biotechnology company, which engages in the development of inhaled treatments against viral infections. Its products include LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well known acetyl salicylic acid. The company was founded by Gerhard Scheuch in 2012 and is headquartered in Gauting, Germany. | Pharmaceuticals: Other | Director/Board Member | |
TOLREMO therapeutics AG
![]() TOLREMO therapeutics AG Miscellaneous Commercial ServicesCommercial Services TOLREMO therapeutics AG engages in discovering and developing therapies for treating cancer patients. The firm serves on academic research laboratories, flourishing life sciences spin-offs and cutting-edge technology platforms. The company was founded by Stefanie Flückiger-Mangual, Wilhelm Krek, Karl-Heinz Altmann, Isaac Kobrin, and Emmanuel Savioz in March 2017 and is headquartered in Zurich, Switzerland. | Miscellaneous Commercial Services | Director/Board Member | |
University of Basel | College/University | Doctorate Degree | |
NewAmsterdam Pharma Holding BV
![]() NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Biotechnology | Director/Board Member | |
F. Hoffmann-La Roche Ltd.
![]() F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Amal Therapeutics SA
![]() Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Biotechnology | Director/Board Member | |
SPEXIS AG | Pharmaceuticals: Major | Director/Board Member |
Statistieken
Internationaal
Zwitserland | 18 |
Verenigde Staten | 16 |
Frankrijk | 8 |
Verenigd Koninkrijk | 4 |
Nederland | 4 |
Sectoraal
Health Technology | 30 |
Consumer Services | 8 |
Commercial Services | 7 |
Finance | 3 |
Technology Services | 3 |
Operationeel
Director/Board Member | 78 |
Founder | 16 |
Chief Executive Officer | 13 |
Independent Dir/Board Member | 11 |
Corporate Officer/Principal | 11 |
Sterkste connecties
- Beurs
- Insiders
- Thomas F. Baumert
- Bedrijfsconnecties